Logo von

News and Events

Scientists from EUCODIS contributed to research published in Nature Catalysis

Improving biocatalytical processes through genetically engineering proteins is one great challenge in today’s biotechnological industry. One new approach regarding this is engineering multiple active sites - both from biological and abiological origin - into one protein. A team around Manuel Ferrer from the Institute of Catalysis in Madrid, Spain together with two members from the research department of EUCODIS have mastered this challenge and could publish their results in the current issue of…

More Information

Novel Catalase for complete neutralization of hydrogen peroxide in agar plates

EUCODIS Bioscience, an established Austrian enzyme engineering and manufacturing company, developed and patented a catalase as a novel neutralizer in environmental monitoring media and offers either a collaboration or OEM supply of the enzyme or the technology itself for licensing.

EUCODIS Bioscience’s patented recombinant catalase formulation is unique as it is the only one worldwide that can be applied to agar plates due to its increased stability at high temperatures (stable at 55°C during…

More Information

ChitoTex and Eucodis Bioscience: Enzyme development for chitosan production

Within the ChitoTex project EUCODIS Bioscience, the Fraunhofer IGB, the Norwegian University of Life Sciences (NMBU) and others collaborated to establish a new enzyme based approach to produce chitosan for the treatment of textile fibers and yarns in a more sustainable way. EUCODIS played an important role in the screening and modification of those enzymes aiming to develop suitable expression systems as well as efficient, stable, recombinant enzymes to produce chitosan.

The Fraunhofer IGB laid…

More Information

EUCODIS Bioscience developed enzyme and enzymatic production method for PrEP Biopharm drug intermediate

EUCODIS Bioscience, an Austrian biotechnology company with strong expertise in industrial enzyme development, announces the completion of a development project for PrEP Biopharm Limited. In this collaboration, EUCODIS Bioscience developed an enzymatic method for production of a drug intermediate of PrEP-001, an immunomodulator for the prevention of the common cold and influenza and supplied key consumables for the GMP manufacturing process.

PrEP Biopharm Limited is a U.K.-based clinical stage,…

More Information

Eucodis starts commercialization of tubulysin A and B

Eucodis Bioscience is glad to announce that it has teamed up with Tube Pharmaceuticals to bring the production of tubulysins to a commercial level. Tube Pharmaceuticals and Eucodis now jointly produce and commercialize tubulysin A and B and other variants of this cytotoxic compound.

Tubulysins are isolated from the culture broth of strains of Archangium gephyra and Angiococcus disciformis, both members of a Gram negative, soil-dwelling group of bacteria known as myxobacteria. The production…

More Information

Antibody Drug Conjugate Using CTAT Linker Technology Shows Superior Efficacy in Xenograft Trial

CTATTM is an innovative enzymatic linker technology for conjugating different payloads with antibodies, without affecting their specificity, binding properties or stability. In the presented xenograft trial, the tested CTAT-ADC showed superior efficacy versus a commercially available ADC.

An anti-Her2 antibody conjugated to the maytansinoid DM1 using the novel CTATTM-linker technology (“CTAT-ADC”) was tested in nude mice with SKOV-3 cancer cell xenografts for maximum tolerated dose (“MTD”) and…

More Information

UPCOMING EVENTS

 

4th European Chemistry Partnering

27 February 2020
Frankfurt, Germany

InCosmetics

31 March - 2 April 2020
Barcelona, Spain